Technical Analysis for HRMY - Harmony Biosciences Holdings, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 31.59 | -1.22% | -0.39 |
HRMY closed down 1.22 percent on Monday, March 18, 2024, on approximately normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. It ran into resistance at its 50 day moving average. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
50 DMA Resistance | Bearish | 0.00% | |
Fell Below 20 DMA | Bearish | 0.00% | |
Fell Below 200 DMA | Bearish | 0.00% | |
Shooting Star Candlestick | Bearish | 0.00% | |
Doji - Bearish? | Reversal | 0.00% | |
50 DMA Resistance | Bearish | -1.22% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -1.22% | |
Crossed Above 20 DMA | Bullish | -1.22% | |
Crossed Above 200 DMA | Bullish | -1.22% | |
Golden Cross | Bullish | -1.22% |
Alert | Time |
---|---|
Up 1% | about 8 hours ago |
50 DMA Resistance | about 10 hours ago |
200 DMA Support | about 10 hours ago |
60 Minute Opening Range Breakout | about 10 hours ago |
Rose Above Previous Day's High | about 10 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 04/30/2024
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc. was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. The company was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Neurological Disorders Stage Pharmaceutical Ethers Urological Disorders Chloroarenes Narcolepsy Piperidines Rare Neurological Disorders Stimulants
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Neurological Disorders Stage Pharmaceutical Ethers Urological Disorders Chloroarenes Narcolepsy Piperidines Rare Neurological Disorders Stimulants
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 45.09 |
52 Week Low | 18.6112 |
Average Volume | 366,142 |
200-Day Moving Average | 31.95 |
50-Day Moving Average | 31.99 |
20-Day Moving Average | 31.69 |
10-Day Moving Average | 30.96 |
Average True Range | 1.41 |
RSI (14) | 49.49 |
ADX | 18.25 |
+DI | 19.75 |
-DI | 22.31 |
Chandelier Exit (Long, 3 ATRs) | 30.94 |
Chandelier Exit (Short, 3 ATRs) | 33.58 |
Upper Bollinger Bands | 33.69 |
Lower Bollinger Band | 29.70 |
Percent B (%b) | 0.47 |
BandWidth | 12.60 |
MACD Line | -0.32 |
MACD Signal Line | -0.31 |
MACD Histogram | -0.0065 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 33.21 | ||||
Resistance 3 (R3) | 33.32 | 32.88 | 32.94 | ||
Resistance 2 (R2) | 32.88 | 32.47 | 32.83 | 32.85 | |
Resistance 1 (R1) | 32.24 | 32.22 | 32.02 | 32.13 | 32.76 |
Pivot Point | 31.80 | 31.80 | 31.70 | 31.75 | 31.80 |
Support 1 (S1) | 31.16 | 31.39 | 30.94 | 31.05 | 30.42 |
Support 2 (S2) | 30.72 | 31.14 | 30.67 | 30.33 | |
Support 3 (S3) | 30.08 | 30.72 | 30.24 | ||
Support 4 (S4) | 29.97 |